AZN News and Press, AstraZeneca PLC From 06/19/24

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the w...

2024-06-18 07:05:27 ET More on AstraZeneca AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZen...

2024-06-17 14:50:10 ET More on FlexShares Trust - FlexShares Quality Dividend Defensive Index Fund: QDEF: FlexShares' Defensive Dividend ETF Fails To Stand Out QDEF: Great Name, But Holdings Don't Validate Seeking Alpha’s Quant Rating on FlexShares Trust - Fle...

2024-06-17 12:41:45 ET More on AstraZeneca AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZen...

2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...

Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy AstraZeneca’s IMFINZI ® (durvalumab) in combination with carboplatin and paclitaxel followed by IMFINZI monotherapy has been app...

First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and...

2024-06-15 10:58:09 ET Summary As expected, AstraZeneca's price has increased in the past quarter, and by a notable 18.4%, following a robust Q1 2024 performance. Recent approvals in the US market, earlier attractive market multiples and a dividend increase also supported the stoc...

2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the...